In addition, B-RAF (V600E) mutation is a driver mutation—it constitutively activates the MAPK/extracellular signal-regulated kinase (ERK) kinase (MEK)-ERK signaling pathway downstream of KRAS (8), which is present in 5–15% of CRC (9). Here, KRAS is linked to colorectal carcinoma.